New understanding of glucocorticoid action in bone cells

Kim, Hyun Ju

doi:10.5483/bmbrep.2010.43.8.524

Cited by 45 publications

(17 citation statements)

References 51 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adipose tissue is the place of secretion of adipokines that influence the metabolic, skeletal, and cardiovascular systems [35]. Bone cells have several specific hormone receptors and can be regarded as a hormone target organ [36,37]. At the same time, OC has been proved to be a factor that may have an effect on body mass control and glucose metabolism [38].…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Relationship between the Levels of Androgens and Biochemical Bone Markers in Men Aged 60–75 Years

Rył

Szylińska

Jurewicz

et al. 2019

IJERPH

View full text Add to dashboard Cite

Introduction: The purpose of this study was to analyze the relationship between the parameters of bone turnover and the levels of hormonal parameters, such as total testosterone (TT), bioavailable and free testosterone (FT), and estradiol (E2) in men. Material and methods: The study group included 63 men with testosterone deficiency syndrome (TDS). The control group consisted of 112 patients without TDS. Enzyme-linked immunosorbent assay (ELISA) was used to determine the levels of osteocalcin (OC), parathyroid hormone (PTH), E2, sex hormone binding globulin (SHBG), dehydroepiandrosterone sulphate (DHEAS), insulin (I), Serum CrossLaps (CtX-I), human procollagen I N-terminal peptide (PINP), and TT. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry. Results: The groups with TSD and without TDS differed in terms of the following parameters: body weight (p = 0.001), BMI (p = 0.003), TT (p = 0.001), FT (p = 0.004), bioavailable testosterone (p = 0.001), E2 (p = 0.003), SHBG (p = 0.003), and PINP (p = 0.004). In the group without TDS, higher PINP levels were accompanied by higher levels of E2 (beta = 0.360, p = 0.002) and TT (beta = 0.389, p = 0.001). In the group without TDS, PINP was positively correlated with E2 (beta = 0.726, p <0.001). Patients with TDS had significantly lower PINP levels (p < 0.004). Conclusions: Analysis of sex hormones and biochemical bone markers in reflecting the quality of the bone tissue in men may suggest a relationship between these parameters. Nevertheless, further research based on a larger sample size is necessary to better describe this relationship.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of the Relationship between the Levels of Androgens and Biochemical Bone Markers in Men Aged 60–75 Years

Rył

Szylińska

Jurewicz

et al. 2019

IJERPH

View full text Add to dashboard Cite

show abstract

“…Unlike, however, the histomorphometry results from the pediatric patients with nephrotic syndrome, our subjects did not have evidence of osteomalacia, as seen by the reduced osteoid thickness and volume. The primary effect of the glucocorticoid treatment in our subjects would appear to be through the reduction in bone formation decreasing osteoblastogenesis, increasing osteoblast apoptosis and inhibiting osteoblast production of bone matrix [36–38]. …”

Section: Discussionmentioning

confidence: 99%

Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids

et al. 2016

View full text Add to dashboard Cite

BackgroundRheumatic diseases are associated with an increased fracture risk. The tissue level characteristics of the bone involvement in children have not been well elucidated. Our objectives were to describe the bone micro-architectural characteristics in children with rheumatic diseases on chronic glucocorticoids, and to determine associations between micro-architectural findings with clinical and radiological variables.MethodsChildren on chronic glucocorticoids for an underlying rheumatic disease were referred for evaluation of bone fragility given the presence of vertebral compression fractures. A trans-iliac bone biopsy was performed as part of the clinical assessment. Histomorphometric analysis and quantitative backscattered electron imaging (qBSE) of the biopsy samples were undertaken.ResultsData of 15 children (14.0 ± 3.2 years) with a duration of glucocorticoid exposure of 6.2 ± 4.1 years and average prednisone dose of 14.1 ± 6.2 mg/m2/day were assessed. Histomorphometric analyses demonstrated significant decrease in trabecular thickness (p = 0.01), osteoid thickness (p < 0.01), osteoblast surface (p = 0.02) and increase in trabecular separation (p = 0.04) compared to published age-matched normative data. Severity of the trabecular deficit was correlated to glucocorticoid dose, height and body mass index Z score, but not bone mineral density or measures of disease activity. Using qBSE to measure bone mineralization, the subjects were shown to have a heterogeneous and hypermineralized profile, with higher cumulative glucocorticoid dose being associated with greater mineralization (p < 0.01).ConclusionsIn children with rheumatic diseases presenting with vertebral fractures, there is evidence of abnormal bone matrix mineralization and impairments of bone micro-architecture that correlate to glucocorticoid dose.

show abstract

“…(52) It has been reported that bone loss occurs with a rapid phase of about 12% within the first year of glucocorticoid administration, followed by a slow phase of 2-5% annually. (53-55) Multiple practice guidelines have been written recommending treatment protocols for patients, including those diagnosed with DMD who are placed on chronic glucocorticoid treatment, to reduce fractures and the morbidity associated with glucocorticoid-induced osteoporosis (see Table 1 and 2). (56-57)…”

Section: Determinants Of Bone Massmentioning

confidence: 99%

Bone Health and Associated Metabolic Complications in Neuromuscular Diseases

Joyce¹,

Hache²,

Clemens³

2012

Physical Medicine and Rehabilitation Clinics of North America

View full text Add to dashboard Cite

Synopsis This article reviews the recent literature regarding bone health as it relates to the patient living with neuromuscular disease (NMD). Poor bone health with related morbidity is a significant problem for patients with NMD. Although the evidence addressing issues of bone health and osteoporosis have increased as a result of the Bone and Joint Decade, studies defining the scope of bone-related disease in NMD are scant. The available evidence is discussed focusing on abnormal calcium metabolism, increased fracture risk, and the prevalence of both scoliosis and hypovitaminosis D in Duchenne muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy. These problems appear common. Osteomalacia often complicates disease-related baseline osteoporosis and may reduce fracture risk if treated. Future directions are discussed, including the urgent need for studies to both determine the nature and extent of poor bone health, and to evaluate the therapeutic effect of available osteoporosis treatments in patients with NMD.

show abstract

New understanding of glucocorticoid action in bone cells

Abstract: Glucocorticoids (GCs

Cited by 45 publications

References 51 publications

Analysis of the Relationship between the Levels of Androgens and Biochemical Bone Markers in Men Aged 60–75 Years

Analysis of the Relationship between the Levels of Androgens and Biochemical Bone Markers in Men Aged 60–75 Years

Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids

Bone Health and Associated Metabolic Complications in Neuromuscular Diseases

Contact Info

Product

Resources

About